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Background: In most of the world, microbiologic diagnosis of tuberculosis (TB) is limited to microscopy. Recent
guidelines recommend culture-based diagnosis where feasible.
Methods: In order to evaluate the relative and absolute incremental diagnostic yield of culture-based diagnosis in a
high-incidence community in Cape Town, South Africa, subjects evaluated for suspected TB had their samples
processed for microscopy and culture over a 21 month period.
Results: For 2537 suspect episodes with 2 smears and 2 cultures done, 20.0% (508) had at least one positive smear
and 29.9% (760) had at least one positive culture. One culture yielded 1.8 times more cases as 1 smear (relative
yield), or an increase of 12.0% (absolute yield). Based on the latter value, the number of cultures needed to
diagnose (NND) one extra case of TB was 8, compared to 19 if second specimens were submitted for microscopy.
Conclusion: In a high-burden setting, the introduction of culture can markedly increase TB diagnosis over
microscopy. The concept of number needed to diagnose can help in comparing incremental yield of diagnosis
methods. Although new promising diagnostic molecular methods are being implemented, TB culture is still the
gold standard.
Keywords: Tuberculosis, Diagnosis, Culture, MicroscopyBackground
For years, the World Health Organization (WHO) and the
International Union against Tuberculosis and Lung Dis-
ease (IUATLD) recommended sputum smear microscopy
as the cornerstone to diagnose pulmonary TB, as smear-
positive subjects are most contagious [1,2]. However, since
smear microscopy has a detection limit of about 5000–10
000 organisms/mL [3] - compared to 10–100 organisms/
mL for culture [4] - specimens with < 5000 bacteria are
negative by microscopy.
In settings where microscopy and culture are both
done, such as developed countries, approximately half of
culture positive specimens have negative smears [5-8].
Based on this, one anticipates a doubling of case detec-
tion if culture methods are introduced into a setting that
only does microscopy.* Correspondence: marcel.behr@mcgill.ca
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reproduction in any medium, provided the orWHO recommends the use of liquid culture in low in-
come settings where feasible [9]. However, other author-
ities consider the role of culture to be primarily for
surveillance and diagnosis of MDR-TB [10]. Little is
known on the yield of culture in the context of national
TB control programmes in high incidence countries. We
have evaluated the relative (RY) and absolute yield (AY)
of introducing culture-based diagnosis in a high inci-
dence setting (Cape Town, South Africa).Methods
Study design
Prospective cohort study in regular programme setting
Study setting This study was conducted in Gugulethu, a
residential area in Cape Town, South Africa, as part of a
molecular epidemiology study. At the time of the study, the
notified incidence of TB was 992/100 000 and the antenatal
HIV prevalence was 28.1% [11]. The setting is still similar
now with respect to incidence rate and proportion of
patients HIV infected [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Definitions
Definition Formula
Relative incremental yield of
method* 1 vs method 2 (RY)
= % positive per method 2
% positive per method 1
Absolute incremental yield of
method 2 vs method 1 (AY)
= % positive per method
2 - % positive per
method 1
Number needed to diagnose one
extra case of TB (NND)
= 1
AY (in %)
Legend: *Method: can either be 1 smear, 2 smears, 1 culture, 2 cultures.
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From 1 April 2002 to 31 December 2003, subjects older
than 14 years presenting to the NY1 Gugulethu TB
clinic with signs or symptoms of pulmonary TB were
considered suspects and included in the study. Because
some individuals presented more than once during the
study period, we analyzed the data by suspect episodes
(SE) and not patients. We defined a new SE if the same
person returned to the clinic more than 6 weeks after a
previous evaluation. A previous analysis describing a
method to assess laboratory cross-contamination has
already been published [13].
Data collection
Routine diagnosis and treatment procedures were followed
by clinical staff, except that culture was added to the
smear-based diagnosis recommended by the South African
TB Guidelines, which restrict cultures to retreatment
cases [14]. Every effort was made to collect 2 sputum
samples for each SE. Additional smears and cultures
were done if judged necessary by the clinic staff.
Chest x-rays were not done routinely as per national
guidelines.
Demographic and laboratory data were collected for
all SE. No supplementary procedures were performed
on patients. For treatment episodes, outcome infor-
mation was obtained from the clinical notes, patient
interviews and the TB register. Patients started on TB
treatment were interviewed by the study team after
informed consent was obtained. Since some patients
might have been treated at another TB clinic in the
area, we manually matched by name and demographic
data the untreated positive culture SE with the sub-
district electronic TB register for July 2002 to Oct
2005.
HIV voluntary counseling and testing was offered to
every patient put on TB treatment. HIV information was
only available for those started on treatment and was
collected from patient interviews and record reviews. At
the time of the study, antiretrovirals were not routinely
available for HIV positive patients. The protocol was
approved by the research ethics committee of the Fac-
ulty of Health Sciences, University of Cape Town (REC
REF 048/2001).
Laboratory procedures
Sputum specimens were collected at the Gugulethu
clinic and kept refrigerated until transported later the
same day to the National Health Laboratory Services
(NHLS) in Cape Town where they were processed for
fluorescence (auramine) microscopy and culture. Smear
results were reported as per WHO/IUATLD classification
[15]. Cultures were done both on one Löwenstein-Jensen
and one BACTEC MGIT 960 W bottle (BD DiagnosticSystems, Sparks, MD) and incubated for 8 weeks. If either
culture method was positive, the sample was reported
positive. Unfortunately, the results for solid and liquid
media were not recorded individually. In addition to bio-
chemical methods, positive cultures were speciated
as M. tuberculosis complex using the AccuprobeW
(Gen-Probe Inc., San Diego, CA). Susceptibility test-
ing for isoniazid (INH) and rifampicin (RIF) was
done using the indirect proportion method. Details
on the laboratory procedure have been described
elsewhere [13].Definitions
Only diagnosis specimens were analysed. We considered
scanty smears to be positive [16-18]. SE with culture
results other than negative or positive for M. tuberculosis
(i.e. non-tuberculous mycobacteria (NTM), lost viability
or contaminated) were excluded from the analysis as it
was not possible to assume with certainty that they were
negative or positive. For each SE, both smear and culture
results were ordered by timing of specimen collection
and classified according to the following patterns of suc-
cessive specimens: N (N = negative), P (P = positive),
NN, NP, PP, PN, NNN, NNP, NPN, NPP, etc. Smear and
culture results were then combined together per SE. A
SE was classified as smear positive if any of the smears
was positive. A SE was classified as culture positive if
any of the cultures was positive for M. tuberculosis com-
plex. Smear and culture results were then grouped to-
gether, defining SE as SNCP (smear negative culture
positive), SPCP (smear positive culture positive), SPCN
(smear positive culture negative) or SNCN (smear nega-
tive culture negative).
Because our study was done under routine conditions,
not all TB suspects had 2 specimens collected. In order
to correctly calculate the incremental yields, we added
the observed proportions of positive smears or cultures
to the expected proportion for the missing specimens,
using a method described by Rieder et al. (Appendix)
[19]. Since less than 10% of SE had a 3rd smear or cul-
ture done, we could not calculate accurately the yields
for the third specimen. We therefore restricted the
3742 consecutive TB suspect
episodes (SE) with at least 1 smear
and 1 culture result available
30 SE with NTM culture results (0.8%)
18 SE with lost viability culture results (0.5%)
578 SE with contaminated culture results (15.4%)
3116 SE
579 SE that have ≥ 3 smears and ≥ 3 cultures done
2537 SE for analysis
(67.8% of 3742)
Figure 1 Study flow diagram. Legend. SE = Suspect Episodes, NTM = Non-tuberculous mycobacteria.
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regrouped our initial patterns of successive specimens
into Rieder’s patterns, adapted for 2 specimens: N9
(where N is negative and 9 is a missing specimen), NN,
NP and Px (where P is positive and x is a subsequent re-
sult of no interest for the calculation of incremental
yields) (Appendix)[19].To calculate the relative and ab-
solute yield of smears and cultures, we used the formu-
las shown in Table 1. We defined the number needed to
diagnose (NND) as the reciprocal of the absolute yield.
We did not use another proposed definition for NND
[20] because it did not consider prevalence [21].
Data analysis
Data were collected and analyzed using Microsoft Ac-
cess 2002 database and Stata software, version 10 (Stata
Corporation). The chi-squared test was used to compare
proportions.
Results
During the study period, 3742 SE had at least 1 smear
and 1 culture done. After excluding the SE which wereTable 2 Smear and culture results per SE for the 1st specimen
1st specimen Culture Afte
P N Total
Smear P 345 32 377 Sme
N 337 1823 2160
Total 682 1855 2537
Se = SPCP / CP 50.6%
Sp = SNCN / CN 98.3%
PPV = SPCP / SP 91.5%
NPV = SNCN / SN 84.4%
Legend: S = smear, C = culture, P = positive, N = negative, Se = Sensitivity, Sp = Spcontaminated, showed the presence of a NTM or lost
viability, and after removing the SE with ≥3 smears or
cultures, 2537 SE were left for analysis (67.8% of 3742)
(Figure 1). These 2537 SE represented 2207 individuals:
62% were male with a median age of 35 years (interquar-
tile range 27–45). Of note, only 1 of the 30 excluded SE
with NTM had a mixed infection with M. tuberculosis.
Smears and cultures results
In Table 2, smear and culture results are presented for
the first and for both specimens (combined field). The
sensitivity of smear compared to culture was 50.6%
and 58.9% respectively. Of the 2537 SE, 20.0% had at
least one positive smear and 29.9% had at least one
positive culture after 2 specimens (expected proportion
of positives in Table 3). Using all smear positive SE as
a denominator, the fraction of SE positive on the first
smear (Fd1) was 74.3% and the incremental yield (IY)
of the second smear (Fd2) was 25.7% (Table 3). For
cultures, 89.8% of positive cultures were positive on
the first specimen, and the IY of the second culture
was 10.2%. The number of specimens needed to findand for both specimens
r 2 specimens Culture (combined)
P N Total
ar (combined) P 432 45 477
N 301 1759 2060
Total 733 1804 2537
Se = SPCP / CP 58.9%
Sp = SNCN / CN 97.5%
PPV = SPCP / SP 90.6%
NPV = SNCN / SN 85.4%
ecificity, PPV = Positive predictive value, NPV = Negative predictive value.
Table 3 Smear and culture results for all SE, smear negative and smear positive SE
Description All smears All cultures Cultures in SN SE Cultures in SP SE
Number of SE 2537 2537 2060 477
Observed # of P SE after 1 specimen 377 682 253 429
Observed # of P SE after 2 specimens 477 733 301 432
Proportion of P SE on 1st specimen 0.149 0.269 0.123 0.899
Proportion of NP SE 0.060 0.042 0.040 0.103
# of P SE missed by failing to do 2nd specimen 31 27 25 2
Expected # of P SE after 1 specimen 377 682 253 429
Expected # of P SE after 2 specimens 508 760 326 434
Expected proportion of P SE after 1 specimen 0.149 0.269 0.123 0.899
Expected proportion of P SE after 2 specimens 0.200 0.299 0.158 0.910
Potential IY for 1st specimen 0.743 0.898 0.776 0.989
Potential IY for 2nd specimen 0.257 0.102 0.224 0.011
Overall fraction of P on 1st specimen 0.149 0.269 0.123 0.899
Overall fraction of P on 2nd specimen 0.052 0.031 0.035 0.010
NND on 1st specimen 7 4 8 1
NND on 2nd specimen 19 33 28 96
Legend: S = smear, P = positive, N = negative, SE = Suspect Episodes, NND = number needed to diagnose (see Methods for details), IY = incremental yield.
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the second smear to the first smear, 19 specimens
would need to be examined before finding another
positive one. For cultures, only 4 specimens would be
needed to find a positive result on the first specimen
but when comparing the yield of the second culture toTable 4 Relative and absolute incremental yields and NND fo
Yield
Expected # of P after 1 S = 377/2537 = 14.9%
Expected # of P after 2 S = 508/2537 = 20.0%
Expected # of P after 1 C = 682/2537 = 26.9%
Expected # of P after 2 C = 760/2537 = 29.9%
Yield
Expected # of P after 1 S = 377/2537 = 14.9%
Expected # of P after 2 S = 508/2537 = 20.0%
Expected # of P after 1 C = 682/2537 = 26.9%
Expected # of P after 2 C = 760/2537 = 29.9%
NND
1st Smear 7
2 Smears total 5
1st Culture 4
2 Cultures total 3
Legend: S = smear, P = positive, N = negative, SE = Suspect Episodes, NND = num
Expected # of P after 1 S or C is same as Observed (see Appendix for details).the first culture, the NND would be 33. Table 4 shows
the results presented as RY, AY and NND to compare
different screening strategies. The relative yield of
doing 1 culture was about twice the yield of 1 smear
(1.8), for an absolute yield of 12.0%, meaning that in
this setting, one can detect one additional case of TBr smear and cultures
Relative incremental yield vs.
1st S 2 S total 1st C
1.3
1.8 1.3
2.0 1.5 1.1
Absolute incremental yield vs.
1st S 2 S total 1st C
5.2%
12.0% 6.9%
15.1% 9.9% 3.1%
NND vs.
1st S 2 S total 1st C
19
8 15
7 10 33
ber needed to diagnose (see Methods for details), IY = incremental yield. Note:
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contrast, one additional case was diagnosed when 19
patients submitted a second sample for smear micros-
copy (Tables 3 and 4).
We compared the culture results of the smear positive
SE to the smear negative SE (Table 3). Smear positive
specimens are expected to be culture positive so yields
are presented mainly as a comparison to the smear nega-
tive SE. Although the potential IY for the first culture
was lower at 77.6% compared to all cultures (89.8%), it is
still very high. The IY for a second culture in smear nega-
tive episodes was 22.4%. Of the 733 culture positive SE,
susceptibility results were available for 639 (87.2%). Of
these, only 7 (1.1%) were resistant to isoniazid and rifam-
picin, precluding further analysis due to small numbers.
HIV results
The HIV status and outcome were available only for
treated patients that had consented to HIV testing: this
represented 345 (13.6%) of the 2537 SE and 302 (41.2%)Table 5 Yields and NND calculated on some other recent stud
Our study Our study SN SE M
Population HIV pos and neg SN in HIV pos and neg Al
Pos on 1st S 377 36
Pos on 2S 508 45
Pos on 1st C 682 253 97
Pos on 2C 760 326 11
TB suspects tested 2537 2060 10
% Pos on 1st S 0.149 0.0
% Pos on 2S 0.200 0.0
% Pos on 1st C 0.269 0.123 0.0
% Pos on 2C 0.299 0.158 0.1
RY 2S vs 1S 1.3 1.3
RY 1C vs 1S 1.8 2.7
RY 1C vs 2S 1.3 2.2
RY 2C vs 1C 1.1 1.3 1.2
AY 2S vs 1S 0.052 0.0
AY 1C vs 1S 0.120 0.0
AY 1C vs 2S 0.069 0.0
AY 2C vs 1C 0.031 0.035 0.0
NND 2S vs 1S 19 11
NND 1C vs 1S 8 17
NND 1C vs 2S 15 20
NND 2C vs 1C 33 28 66
NND of 1st S 7 29
NND of 1st C 4 8 11
Legend: S = smear, C = culture, Pos = positive, Neg = negative, RY = Relative yield
diagnose. In the study by Monkongdee et al. [32], yields were reported using all cu
suspects tested as the denominator.of the 733 culture confirmed SE. More than half of these
345 SE were HIV infected (192/345 = 55.7%). The yield
of the first smear was 38.5% in HIV positive patients
(74/192) compared to 51.0% (78/153) in HIV negative
patients (chi-square = 5.34, p = 0.021). For HIV infected
patients, the relative yield of 1 culture compared to 1
smear was higher than in HIV negative patients, with a
relative yield of 2.1, an absolute yield of 43.2% and a
NND of 2.3 (data not shown). However, these results
should be interpreted with caution since the HIV status
was known for only a small proportion of TB suspects.
Discussion
When culture was added to the routine smear-based
diagnosis of TB suspects in a high incidence area of
South Africa, we found that 29.9% of 2537 SE were
culture positive, compared to 20.0% for smear micros-
copy. The relative yield of culture-based diagnosis was
almost double, consistent with the observation that mi-
croscopy typically has a sensitivity of about 50% whenies that have used culture based diagnosis in TB suspects
onkongdee et al. [32] Boehme et al. [36] Ssengooba et al. [35]
l HIV pos HIV pos and neg All HIV pos and SN
561
732 52
3 60
60 1462 170
34 0.384
42
92 0.501 0.306
07 0.353
1.3
1.2
08
58 0.117
49
15 0.047
8
9
21
3
2 3
, AY = Absolute yield, SE= suspect episode, NND = number needed to
lture positive cases as the denominator. The results shown here use all
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can obtain an additional TB diagnosis with just 8 cul-
tures, or alternatively by submitting 19 second speci-
mens for microscopy.
Although smear is less sensitive than culture, never-
theless it has excellent PPV in high incidence areas [3].
Our data indicate that while many patients can be
detected by microscopy in a high-prevalence setting
[22], the addition of culture-based diagnosis can detect
many more. Moreover, the present study used the more
sensitive fluorescent technique to define a microscopy-
positive sample; the incremental yield of culture should
be even greater in settings that do only light microscopy.
Reviews on the sensitivity of smear compared to culture
are based mainly on laboratory-based studies from
developed countries, often with no description of the pa-
tient population studied [5,7,23]. If smears and cultures
were performed and read exactly the same way on speci-
mens from clinically similar patients in a low then in
high TB prevalence area, we should observe similar sen-
sitivity. However, because of the higher prevalence of
positive smear and culture results observed in high en-
demic areas, the absolute and relative benefit will also
increase, while the NND decreases. Paradoxically, coun-
tries with the lowest rates of TB typically do both mi-
croscopy and culture, while countries with the highest
rates of TB often forego culture due to costs and lack of
needed infrastructure. Our data supports recent state-
ments by the WHO [9,24-27] and the International
Standards for TB Care [28] on the use of culture in low
income settings, recognizing that for each setting theTable 6 Definitions and formulas used for yield calculations
Description
Ad Number of SE who had specimens examined
Observed # of P SE after 1 specimen
Od Observed # of P SE after 2 specimens
Sd1 Fraction of SE found positive on the 1st specimen
Sd2 Fraction of SE found to be negative on the 1st specimen bu
Md # of P SE missed by failing to do a 2nd specimen
Expected # of P SE after 1 specimen: same as Observed # o
Ed Expected # of P SE after 2 specimens (if all suspects had 2 s
Expected proportion of P SE after 1 specimen: same as Sd1
Rd Expected proportion of P SE after 2 specimens
Fd1 Fraction for the potential IY from the 1st specimen
Fd2 Fraction for the potential IY from the 2nd specimen
OFP1 Overall fraction of P on 1st specimen
OFP2 Overall fraction of P on 2nd specimen
NND1 NND on 1st specimen: number of specimens needed to be
NND2 NND on 2nd specimen
Appendix Legend. # = Number, P = positive, SE = Suspect Episodes, NND = numbincremental yield will need to be assessed against the in-
cremental cost of culture-based testing.
In our study, almost 90% of positive cultures were
positive on the first specimen, and the IY of the second
culture was 10%. A lower yield (77.6%) was observed for
the first specimen in smear negative SE compared to
smear positive SE. These findings were also reported in
studies that performed 3 cultures on patients [23,29-31].
However, finding 77% of culture positive patients with
the first specimen is still significant and much more in-
formative than a negative smear result. Table 5 compares
our results to some other studies that have performed
cultures in TB suspects and where results for first and
second specimens were reported. The RY of 1C vs 1S
was higher (2.7) in a study performed in HIV patients in
Thailand and Vietnam [32], most likely because of the
lower yield of light microscopy (Ziehl-Nielsen) com-
pared to fluorescent microscopy.
There were several limitations to our study. First, our
analysis was done on 68.9% of the 3742 TB suspects with
at least 1 smear and 1 culture result. This shows the chal-
lenges of obtaining 2 samples per TB suspect in regular
programme settings. However, we were able to estimate
the proportion of positives for the missing specimens
using established formulas [19]. We excluded 15.4% of SE
with contaminated culture results from our analysis in
order to calculate the yield of first and second specimens
accurately . Lower or similar contamination rates have
been reported with the MGITW system: 8.6% [33], 13%
[32], 16.9% [34], 16.4% [35]. Despite excluding these con-
taminated results, we were nevertheless able to analyse aFormula
Px + NP + NN + N9
Px
Px + NP
Px/(Px + NP + NN + N9)
t positive on the 2nd NP/(NP + NN + N9)
Sd2 * N9
f P SE after 1 specimen
pecimens done) Od + Md
Ed/Ad
Px / Ed
(Md + NPx) / Ed
Rd * Fd1
Rd * Fd2
examined to find one additional case 1/OFP1
1/OFP2
er needed to diagnose.
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have an impact on costs and patient management [34].
Second, the HIV status was available only for treated
patients that had consented to HIV testing, or 13.6% of
2537 SE. HIV voluntary counseling and testing (VCT) was
offered at the clinic but low rates could be explained by
the absence of routinely available antiretroviral therapy at
the time of the study. Third, we were not able to compare
the yield of the solid vs liquid culture media, as the indi-
vidual results for these were not available. However, other
studies have shown the higher yield of liquid vs solid cul-
ture [32-34]. Finally, some inconsistency rates in smear
results were observed. When using all smear positive SE
as a denominator, the proportion of SE positive on the
first smear was 74.3%, lower than the 85% reported in a
meta-analysis [8]. This may be due to the setting of the
study in a regular programme. However, the incremental
yield of culture over microscopy in this study is not due to
false-positive cultures due to laboratory cross-contamin-
ation. We have assessed this possibility in another manu-
script, using dummy samples, and found that the
specificity of culture in this setting is 98.9%, which is com-
parable to other rates described in the literature [13].
Recently, a novel and simple nucleic-acid amplification
test (XpertW MTB/RIF) has been developed [36] and
endorsed by WHO for global implementation [37]. Per-
forming 1 Ziehl–Neelsen smear, 1 XpertWMTB/RIF and 1
liquid culture on TB suspects yielded 38.4%, 46.2% and
50.1% positive results respectively. Compared to doing 1
smear, the RY, AY and NND would be 1.2, 7.8% and 13 for
the XpertW MTB/RIF and 1.3, 11.7% and 9 for culture
[36]. However, as stated by WHO, the Xpert MTB/RIF
technology does not eliminate the need for conventional
microscopy culture and drug susceptibility testing [37].
The rapidity and simplicity of the method are clear advan-
tages. However, sensitivity in smear negative patients
remains an issue, with some reported sensitivities of 43.4%
[38], 54.5% [39] and 72.5% [36]. Furthermore, drug sus-
ceptibility testing is still required to detect resistance to
drugs other than rifampicin [37]. As the Xpert technique
is implemented, initial studies show it can potentially be
cost-effective compared to sputum smear diagnosis and
clinical diagnosis in smear-negative cases [40]. Future
studies could evaluate the cost-effectiveness of smear ver-
sus Xpert, as compared with smear versus culture, or even
the integration of two of these tests. Depending on the
prevalence of positive samples by new diagnostic techni-
ques, the NND can be determined for either test, in order
to predict the incremental gain in case detection, and ul-
timately, the impact on patient care.
Conclusions
In conclusion, in a high TB burden setting, the use of
culture methods can almost double the number ofmicrobiologically-confirmed cases of TB, with just under
8 cultures required to detect 1 additional case.
Appendix
Yield calculations (adapted from Rieder et al. [19]).
There are 6 possible patterns among those who had a
diagnostic examination (Ad) in a setting where 3 speci-
mens are required: Px, NPx, NNP, NN, NN9 and N99,
where P is a positive smear, x a subsequent result of no
interest, N a negative result, and 9 a missing result. For
our study, since we aimed to collect 2 specimens and
since less than 10% of SE had ≥ 3 smears or 3 cultures
done, we kept 4 patterns (Px, NP, NN and N9) and
adapted the formulas accordingly.
To calculate the incremental yields, the assumption
was made that those with an N9 result had the same
probability of being positive on the second smear as
those with an NP result. Those (positive) missed by fail-
ing to do a second smear examination will be denoted as
Md (Table 6).
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